Response to crizotinib and cabozantinib in stage IV lung adenocarcinoma patients with mutations that cause MET exon 14 skipping Meeting Abstract


Authors: Paik, P. K.; Drilon, A. E.; Yu, H. A.; Krug, L. M.; Rekhtman, N.; Borsu, L.; Ginsberg, M. S.; Berger, M. F.; Ladanyi, M.; Rudin, C. M.
Abstract Title: Response to crizotinib and cabozantinib in stage IV lung adenocarcinoma patients with mutations that cause MET exon 14 skipping
Meeting Title: 51st Annual Meeting of the American Society of Clinical Oncology (ASCO)
Journal Title: Journal of Clinical Oncology
Volume: 33
Issue: 15 Suppl.
Meeting Dates: 2015 May 29-Jun 2
Meeting Location: Chicago, IL
ISSN: 0732-183X
Publisher: American Society of Clinical Oncology  
Date Published: 2015-05-20
Language: English
ACCESSION: WOS:000358036901734
PROVIDER: wos
DOI: 10.1200/JCO.2015.33.15_suppl.8021
Notes: Meeting Abstract: 8021 -- Source: Wos
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Natasha Rekhtman
    428 Rekhtman
  2. Michelle S Ginsberg
    236 Ginsberg
  3. Lee M Krug
    178 Krug
  4. Helena Alexandra Yu
    285 Yu
  5. Marc Ladanyi
    1330 Ladanyi
  6. Paul K Paik
    255 Paik
  7. Michael Forman Berger
    768 Berger
  8. Alexander Edward Drilon
    634 Drilon
  9. Charles Rudin
    491 Rudin